NPHC: AI 评分 61/100 — AI 分析 (4月 2026)

Nutra Pharma Corp. is a biopharmaceutical company focused on acquiring, licensing, and commercializing products for pain management, neurological disorders, cancer, and autoimmune diseases. Their product line includes Nyloxin and Pet Pain-Away, targeting both human and animal pain relief.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

Nutra Pharma Corp. operates in the specialty and generic drug manufacturing sector, focusing on pain management and neurological disorders. The company commercializes products like Nyloxin and Pet Pain-Away, targeting both human and animal markets with homeopathic and ethical drugs, primarily within the United States.

NPHC是做什么的？

Nutra Pharma Corp., incorporated in 2000 and based in Plantation, Florida, is a biopharmaceutical company engaged in acquiring, licensing, and commercializing pharmaceutical products and technologies. The company focuses on homeopathic and ethical drugs aimed at managing pain, neurological disorders, cancer, and autoimmune and infectious diseases, primarily in the United States. Its key products include the Nyloxin line, featuring oral sprays and topical gels designed to alleviate pain associated with lower back issues, migraines, arthritis, and repetitive stress. The company also offers Pet Pain-Away, a homeopathic pain reliever for companion animals, and Luxury Feet, targeting pain from wearing high heels. Additionally, Nutra Pharma is developing RPI-78M for neurological and autoimmune diseases, RPI-MN for viral diseases including HIV/AIDS and herpes, and RPI-78 and RPI-70 for pain and arthritis. The company aims to provide alternative and effective treatments in areas with unmet medical needs.

NPHC的投资论点是什么？

Nutra Pharma Corp. operates with a high profit margin of 1865.7% and a gross margin of 56.8%. The company's focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet could provide growth opportunities. However, the company's OTC listing and small market capitalization present liquidity and transparency concerns. The success of their drug development pipeline, including RPI-78M and RPI-MN, is critical for long-term growth. Investors should closely monitor the company's ability to navigate the regulatory landscape and secure partnerships for commercializing its products.

NPHC在哪个行业运营？

Nutra Pharma Corp. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The market for pain management products is substantial, driven by an aging population and increasing prevalence of chronic conditions. Companies in this space must navigate complex FDA approval processes and compete with established pharmaceutical giants. Nutra Pharma's focus on homeopathic and niche products differentiates it from larger players, but also presents challenges in terms of market acceptance and scalability.

Drug Manufacturers - Specialty & Generic

Healthcare

NPHC有哪些增长机遇？

Expansion of the Nyloxin product line into new markets and applications represents a significant growth opportunity. The market for pain relief products is substantial, with a global market size estimated at billions of dollars. By targeting specific pain conditions and demographics, Nutra Pharma can capture a larger share of this market. The company's focus on non-narcotic pain relief alternatives aligns with the growing demand for safer pain management options.
Development and commercialization of RPI-78M for neurological and autoimmune diseases could be a major growth driver. The market for treatments for conditions like multiple sclerosis and rheumatoid arthritis is substantial, with significant unmet medical needs. Successful clinical trials and regulatory approval could lead to substantial revenue growth for Nutra Pharma. This represents a high-risk, high-reward opportunity with a multi-year timeline.
Leveraging the Pet Pain-Away product line to capitalize on the growing pet healthcare market. The pet healthcare market is experiencing rapid growth, driven by increased pet ownership and willingness to spend on pet health. By expanding the distribution channels and marketing efforts for Pet Pain-Away, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.
Strategic partnerships with pharmaceutical companies or distributors to expand the reach of Nutra Pharma's products. Collaborations with established players in the pharmaceutical industry can provide access to larger markets and distribution networks. This can accelerate the commercialization of Nutra Pharma's products and increase revenue growth. Identifying and securing suitable partners is crucial for realizing this growth opportunity.
Expansion of the Luxury Feet product line into new retail channels and geographic markets. The market for foot care products is substantial, driven by the increasing awareness of foot health and the growing demand for specialized products. By expanding the distribution channels and marketing efforts for Luxury Feet, Nutra Pharma can tap into this growing market. This represents a relatively low-risk growth opportunity with a shorter timeline.

Profit Margin of 1865.7% indicates high profitability on sales.
Gross Margin of 56.8% suggests efficient cost management in product sales.
P/E Ratio of 0.25 suggests the company may be undervalued relative to its earnings.
Beta of -2.90 indicates the stock price moves inversely to the market, potentially offering diversification benefits.
Focus on niche markets like homeopathic pain relief for pets and specialized pain management products like Luxury Feet.

NPHC提供哪些产品和服务？

Acquires and licenses pharmaceutical products and technologies.
Commercializes homeopathic and ethical drugs.
Develops treatments for pain management.
Creates products for neurological disorders.
Offers solutions for cancer and autoimmune diseases.
Provides pain relief products for both humans and animals.

NPHC如何赚钱？

Acquires or licenses rights to pharmaceutical products and technologies.
Manufactures and markets its own branded products, such as Nyloxin and Pet Pain-Away.
Generates revenue through direct sales and distribution agreements.
Focuses on niche markets within the pain management and neurological disorder sectors.

Individuals seeking pain relief from conditions like arthritis, back pain, and migraines.
Pet owners looking for homeopathic pain relief for their animals.
Retailers and distributors who sell Nutra Pharma's products.
The United States Military and Veteran's Administration through Nyloxin Military Strength.

Proprietary formulations for products like Nyloxin and Pet Pain-Away.
Focus on niche markets with limited competition.
Established brand recognition in specific product categories.
Intellectual property rights for certain drug candidates.

什么因素可能推动NPHC股价上涨？

Upcoming: Clinical trial results for RPI-78M in treating neurological diseases could drive investor interest.
Upcoming: Potential partnerships with pharmaceutical companies for expanded distribution.
Ongoing: Expansion of the Nyloxin product line into new markets.
Ongoing: Increasing sales of Pet Pain-Away in the growing pet healthcare market.
Ongoing: Regulatory approvals for new indications of existing products.

NPHC的主要风险是什么？

Potential: Intense competition from established pharmaceutical companies.
Potential: Regulatory hurdles and FDA approval processes.
Potential: Product liability claims.
Ongoing: Limited financial resources and small market capitalization.
Ongoing: OTC listing with associated liquidity and transparency concerns.

NPHC的核心优势是什么？

Proprietary formulations for pain relief products.
Focus on niche markets with limited competition.
High profit margin of 1865.7%.
Established brand recognition in specific product categories.

NPHC的劣势是什么？

Small market capitalization and limited financial resources.
OTC listing with associated liquidity and transparency concerns.
Dependence on a limited number of products.
Limited number of employees (4).

NPHC有哪些机遇？

Expansion of the Nyloxin product line into new markets.
Development and commercialization of RPI-78M for neurological diseases.
Leveraging the Pet Pain-Away product line in the growing pet healthcare market.
Strategic partnerships with pharmaceutical companies or distributors.

NPHC面临哪些威胁？

Intense competition from established pharmaceutical companies.
Regulatory hurdles and FDA approval processes.
Potential for product liability claims.
Changes in consumer preferences and market trends.

NPHC的竞争对手是谁？

CBD Life Sciences Inc — Focuses on CBD-based products. — (CBDL)
China Health Industries Holding, Inc. — Operates in the health and wellness sector. — (CHNC)
Can-Am Wellness Corp. — Focuses on health and wellness products. — (CNNA)
Deka Biosciences, Inc. — Develops targeted immunotherapies. — (DKSC)
EVIO, Inc. — Provides testing and analysis services for cannabis and hemp. — (EVIO)

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: Michael D. Flax
Headquarters: Plantation, US
Employees: 4
Founded: 2001

AI Insight

AI analysis pending for NPHC

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Nutra Pharma Corp. do?

Nutra Pharma Corp. is a biopharmaceutical company that acquires, licenses, and commercializes pharmaceutical products and technologies, focusing on homeopathic and ethical drugs for pain management, neurological disorders, cancer, and autoimmune diseases. Their primary products include the Nyloxin line, used for pain relief in humans, and Pet Pain-Away, a homeopathic pain reliever for companion animals. The company also develops novel therapies like RPI-78M for neurological diseases and RPI-MN for viral infections, targeting unmet medical needs in these areas.

What do analysts say about NPHC stock?

As of 2026-03-15, formal analyst coverage of Nutra Pharma Corp. (NPHC) is limited due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 0.25 and a high profit margin of 1865.7%. Growth considerations center on the successful development and commercialization of its drug pipeline and expansion of its existing product lines. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed stocks.

What are the main risks for NPHC?

Nutra Pharma Corp. faces several risks, including intense competition from larger pharmaceutical companies, regulatory hurdles in obtaining FDA approvals, and potential product liability claims. As an OTC-listed company, NPHC also faces liquidity and transparency concerns. The company's limited financial resources and dependence on a small number of products further amplify these risks. Investors should carefully assess these factors before investing in NPHC.